Overview
BIOKIN (2615)
Sichuan Biokin Pharmaceutical Co.,Ltd. engages in the research and development, production, and supply of biomedicine in the fields of antibody drug conjugate,...
- Open
- --
- High
- --
- Low
- --
- Prev. Close
- --
- Volume
- 0
- Turnover
- 0
- Avg Price
- --
- Bid/Ask Ratio
- --
- Amplitude
- --
- 52wk High
- --
- Volume Ratio
- 0.00
- Turnover Ratio
- --
- 52wk Low
- --
- HK Mkt Cap
- --
- Market CapHKD
- --
- P/ETTM
- Loss
- P/EDynamic
- Loss
- P/EStatic
- --
- EPSTTM
- -2.29
- EPSDynamic
- -1.78
- EPSStatic
- --
- BVPS
- 18.99
- P/B
- --
- HK Shares
- 8.63M
- Dividend YieldTTM
- --
- DividendTTM
- --
- Shares
- 421.51M
- Min lot size
- 100
- Currency
- HKD
News
Quartr · Sichuan Biokin Pharmaceutical Co: Q3 earnings rebounded, while 9M losses and R&D-driven cash outflow remained substantial
StockTitan · Izalontamab Brengitecan (Iza-Bren) Doubles Median Progression-Free Survival in Patients with Previously-Treated EGFR-Mutated Non-Small Cell Lung Cancer Compared to Chemotherapy in the Phase 3 PANKU-Lung01 Study | BMY Stock News
Global Report · Sa Sa International Q1 Revenue Jumps 24% as Hong Kong Equities Show Mixed Recovery
Unusual Whales · SystImmune Announces Second Approval of Iza-bren in China for the Treatment of Recurrent or Metastatic Esophageal Squamous Cell Carcinoma
Global Report · Mobile’s Cash Flow Surges 128% as Gome Resorts to Share Issuance for Debt Survival
prnewswire · 15:07 ETSystImmune Announces First Approval of Iza-bren for the Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma in China
